Gentian and research partners with two posters related to the value of calprotectin in management of COVID-19 patients at the AACC

14. Dec 2020 | 4 min read

Moss, 14.12.2020
 
Gentian Diagnostics AS is pleased to announce that two new posters, with data from studies in collaboration with research partners in Sweden and Spain, have been accepted and published at the 2020 AACC Annual Scientific Meeting & Clinical Lab Expo. Presented results confirm the value of calprotectin in management of COVID-19 patients.
 
A challenge with the care of patients with the severe form of COVID-19 is to ensure availability of enough intensive care unit (ICU) beds and ventilators for those patients who will need such high level of care. The two posters present research results showing that the biomarker calprotectin can be used in the risk assessment and prediction of which patients are at risk of developing severe complications such as failure of the respiratory system and mortality. This information can support hospitals to better allocate essential resources.

 

Poster #1289: Plasma calprotectin levels are increased in COVID-19 patients admitted to ICU and correlate with endothelial cell damage


The aim of the study, conducted in collaboration with Akademiska University Hospital in Uppsala, Sweden, has been to evaluate performance of calprotectin in prediction of disease severity in ICU-treated COVID-19 patients. 121 patients admitted with SARS-CoV-2 infections to the ICU were included in the observational study together with ten controls, pre-operative cancer patients treated at the same ICU. The analysis of plasma calprotectin was performed with Gentian’s immunoassay GCAL®.

The ICU patients with confirmed COVID-19 had significantly higher calprotectin levels compared with ICU patients without COVID-19. Calprotectin was able to differentiate between COVID-19 and non-COVID-19 patients with a sensitivity of 93% and specificity of 100%. Furthermore, calprotectin levels correlated with the levels of other inflammatory biomarkers and as a biomarker for endothelial cell damage, indicating the prognostic value of calprotectin in subsequent organ failure. As the release of calprotectin from neutrophils is very rapid in response to infections, calprotectin may be used as an early marker for neutrophil activation in COVID-19 infections.

 

Poster #1255: Circulating Levels Calprotectin for Prediction of Disease Severity in Hospitalized COVID-19 Patients


The prospective, observational study, conducted in collaboration with Santa Lucia Hospital in Cartagena, Spain, examined the value of serum calprotectin for prediction of in-hospital mortality and the need for mechanical ventilation (MV) in 66 patients with confirmed SARS-CoV-2 infection. The analysis of calprotectin was performed with Gentian’s immunoassay GCAL®.

The results show that calprotectin levels were significantly higher in COVID-19 patients who required mechanical ventilation and/or died compared to patients with non-severe form of COVID-19. These findings suggest that calprotectin might have a prognostic role in the risk assessment of COVID-19 patients.

In this study, the performance of calprotectin was compared with other tests for COVID-19 severity that are currently in use. Out of the other tests that have been studied, only a test for C-reactive protein (CRP) was able to predict both patients’ need for mechanical ventilation and mortality as accurately as calprotectin.

 

Please find the posters here: 

Poster 1255: Circulating Levels Calprotectin for Prediction of Disease Severity in Hospitalized COVID-19 Patients

Poster 1289: Plasma calprotectin levels are increased in COVID-19 patients admitted to ICU and correlate with endothelial cell damage

 

For further information contact:
Hilja Ibert CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone: +47 919 06 525

 

MeldingsID: 520454

https://newsweb.oslobors.no/message/520454 

You may also read


Feb 11, 2021 - Kristin Hart

4Q 2020 Results and preliminary annual report

Moss, 11 February 2020 Gentian Diagnostics AS announces its results for the 4th quarter and 2020 preliminary..

Jan 22, 2021 - Kristin Hart

SARS-CoV-2 antibody test moving to the next development phase

Moss, 22.01.2021 Gentian Diagnostics AS is pleased to announce that its high-throughput SARS-CoV-2 antibody..